Key Takeaways
- • Apollo Global Management is in advanced talks to acquire Johnson & Johnson's DePuy Synthes orthopedics unit in a transaction valued at approximately $20 billion, according to Bloomberg reporting from September 11-12, 2026.
- • The potential deal aligns with J&J's previously announced October 2025 strategic decision to separate its orthopedics business, with the separation targeted for completion by 2027.
- • DePuy Synthes is J&J's "hips-and-knees" business, representing a significant orthopedic device and surgical solutions portfolio that J&J has been actively seeking to divest.
- • The transaction would represent a major acquisition by Apollo Global Management, a leading alternative investment manager, marking potential expansion into the medical device sector.
- • J&J's stock traded higher in after-hours activity following the announcement of acquisition discussions, reflecting investor confidence in the divestiture strategy.
Summary
Apollo Global Management is in substantive negotiations to acquire Johnson & Johnson's DePuy Synthes orthopedics unit in a potential transaction valued near $20 billion. The discussions, reported by Bloomberg on September 11-12, 2026, represent a concrete development in J&J's previously outlined portfolio restructuring strategy. In October 2025, J&J announced its intention to separate the orthopedics business, with a targeted completion date of 2027. The current Apollo discussions suggest the company is actively pursuing a sale transaction rather than a spin-off, accelerating the strategic timeline.
DePuy Synthes represents J&J's core orthopedic device and surgical solutions platform, commonly referenced as its "hips-and-knees" business. This unit has been a significant revenue contributor within J&J's medical devices segment, making it a meaningful strategic asset in the broader healthcare investment landscape. The $20 billion valuation indicates substantial enterprise value for a standalone orthopedics business, reflecting the market's assessment of the unit's competitive position and cash generation potential.
Apollo Global Management's potential acquisition would represent a major expansion beyond its traditional alternative investment platforms. The Wall Street Journal separately confirmed the ongoing negotiations, broadening market awareness of the transaction discussions. Following announcement of the talks, J&J stock moved higher in after-hours trading, suggesting investor approval of the divestiture strategy. The separation remains on track for completion by 2027, providing both parties with a defined timeline for transaction execution and integration planning.
DePuy Synthes represents J&J's core orthopedic device and surgical solutions platform, commonly referenced as its "hips-and-knees" business. This unit has been a significant revenue contributor within J&J's medical devices segment, making it a meaningful strategic asset in the broader healthcare investment landscape. The $20 billion valuation indicates substantial enterprise value for a standalone orthopedics business, reflecting the market's assessment of the unit's competitive position and cash generation potential.
Apollo Global Management's potential acquisition would represent a major expansion beyond its traditional alternative investment platforms. The Wall Street Journal separately confirmed the ongoing negotiations, broadening market awareness of the transaction discussions. Following announcement of the talks, J&J stock moved higher in after-hours trading, suggesting investor approval of the divestiture strategy. The separation remains on track for completion by 2027, providing both parties with a defined timeline for transaction execution and integration planning.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.